DK1220856T3 - Pyrazolo[4,3-d]pyrimidinderivater - Google Patents

Pyrazolo[4,3-d]pyrimidinderivater

Info

Publication number: DK1220856T3
Authority: DK; Denmark
Prior art keywords: pyrazolo; pyrimidine derivatives; pyrimidine; derivatives
Prior art date: 1999-10-11

Application number

DK00966347T

Other languages

English (en)

Inventor

Mark Edward Bunnage

Keith Michael Devries

Laurence James Harris

Philip Charles Levett

John Paul Mathias

Joanna Teresa Negri

Stephen Derek Albert Street

Albert Shaw Wood

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-11

Filing date

2000-10-11

Publication date

2005-03-14

1999-10-11 Priority claimed from GBGB9924063.2A external-priority patent/GB9924063D0/en

2000-07-28 Priority claimed from GB0018656A external-priority patent/GB0018656D0/en

2000-10-11 Application filed by Pfizer filed Critical Pfizer

2005-03-14 Application granted granted Critical

2005-03-14 Publication of DK1220856T3 publication Critical patent/DK1220856T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK00966347T 1999-10-11 2000-10-11 Pyrazolo[4,3-d]pyrimidinderivater DK1220856T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9924063.2A GB9924063D0 (en)	1999-10-11	1999-10-11	Pharmaceutically active compounds
GB0018656A GB0018656D0 (en)	2000-07-28	2000-07-28	Pharmaceutically active compounds
PCT/IB2000/001457 WO2001027113A2 (en)	1999-10-11	2000-10-11	PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number	Publication Date
DK1220856T3 true DK1220856T3 (da)	2005-03-14

Family

ID=26244757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00966347T DK1220856T3 (da)	1999-10-11	2000-10-11	Pyrazolo[4,3-d]pyrimidinderivater

Country Status (49)

Country	Link
US (4)	US6677335B1 (da)
EP (1)	EP1220856B1 (da)
JP (1)	JP3834236B2 (da)
KR (1)	KR100549152B1 (da)
CN (3)	CN100378100C (da)
AP (1)	AP1238A (da)
AT (1)	ATE284404T1 (da)
AU (1)	AU779065B2 (da)
BG (1)	BG106678A (da)
BR (1)	BR0014698A (da)
CA (1)	CA2387357C (da)
CO (1)	CO5251477A1 (da)
CR (2)	CR6617A (da)
CU (1)	CU23198A3 (da)
CZ (1)	CZ20021158A3 (da)
DE (1)	DE60016615T2 (da)
DK (1)	DK1220856T3 (da)
DZ (1)	DZ3220A1 (da)
EA (1)	EA004982B1 (da)
EE (1)	EE05181B1 (da)
EG (1)	EG24411A (da)
ES (1)	ES2232502T3 (da)
GE (2)	GEP20033142B (da)
GT (1)	GT200000171A (da)
HK (3)	HK1050367A1 (da)
HR (1)	HRP20020317B1 (da)
HU (1)	HUP0203450A3 (da)
IL (2)	IL149026A0 (da)
IN (4)	IN2002MU00385A (da)
IS (1)	IS2181B (da)
MA (1)	MA26825A1 (da)
MX (1)	MX228340B (da)
MY (1)	MY130319A (da)
NO (1)	NO322856B1 (da)
NZ (1)	NZ518078A (da)
OA (1)	OA12061A (da)
PA (1)	PA8504501A1 (da)
PE (1)	PE20010737A1 (da)
PH (1)	PH12000002783B1 (da)
PL (1)	PL357536A1 (da)
PT (1)	PT1220856E (da)
RS (1)	RS50476B (da)
SI (1)	SI1220856T1 (da)
SK (1)	SK4602002A3 (da)
SV (1)	SV2002000195A (da)
TN (1)	TNSN00199A1 (da)
TR (1)	TR200200989T2 (da)
TW (1)	TWI265925B (da)
WO (1)	WO2001027113A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235625B2 (en)	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB0000561D0 (en) *	2000-01-11	2000-03-01	Pfizer Ltd	Treatment of diabetic ulcers
AU5714601A (en) *	2000-04-19	2001-10-30	Univ Johns Hopkins	Methods for prevention and treatment of gastrointestinal disorders
US6271228B1 (en) *	2000-04-28	2001-08-07	Pfizer Inc.	Blood pressure stabilization during hemodialysis
US6407259B1 (en)	2000-07-28	2002-06-18	Pfizer Inc.	Process for the preparation of pyrazoles
US6420557B1 (en)	2000-07-28	2002-07-16	Pfizer Inc.	Crystalline therapeutic agent
WO2002010171A1 (en) *	2000-07-28	2002-02-07	Pfizer Limited	Crystalline therapeutic agent
EP1176142A1 (en) *	2000-07-28	2002-01-30	Pfizer Inc.	Process for the preparation of pyrazoles
GB0025782D0 (en) *	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
US6548508B2 (en)	2000-10-20	2003-04-15	Pfizer, Inc.	Use of PDE V inhibitors for improved fecundity in mammals
FR2820319B3 (fr) *	2001-02-08	2003-12-05	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
JP2005529927A (ja) *	2002-05-23	2005-10-06	ファイザーインコーポレイテッド	新規な組み合わせ
GB0214784D0 (en) *	2002-06-26	2002-08-07	Pfizer Ltd	Novel combination
DE10229778A1 (de) *	2002-07-03	2004-01-29	Bayer Ag	Neue Verwendung von Imidazotriazinonen
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
JP2006511606A (ja)	2002-12-13	2006-04-06	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	下部尿路症状を治療するα−２−δリガンド
AR043416A1 (es)	2003-02-27	2005-07-27	Uriach Y Compania S A J	Un compuesto que comprende derivados de pirazolopiridina, procedimiento para preparar dicho compuesto y sus usos en la manufactura de medicamentos y composiciones farmaceuticas
AU2004234158B2 (en)	2003-04-29	2010-01-28	Pfizer Inc.	5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
CA2528975A1 (en) *	2003-06-10	2004-12-16	Pfizer Inc.	Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
JP2006219373A (ja) *	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE10360835A1 (de) *	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2562251C (en)	2004-04-07	2009-04-28	Pfizer Inc.	Pyrazolo'4,3-d pyrimidines
DE602006003416D1 (de)	2005-03-21	2008-12-11	Pfizer Ltd	Substituierte triazolderivate als oxytocinantagonisten
NZ564187A (en)	2005-05-12	2010-03-26	Pfizer	Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
US8273750B2 (en)	2005-06-06	2012-09-25	Takeda Pharmaceutical Company Limited	Organic compounds
EP1928437A2 (en)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
CA2625210A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
RU2008120332A (ru) *	2005-12-20	2010-01-27	Пфайзер Продактс Инк. (Us)	Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист
EP1968705A1 (en) *	2005-12-21	2008-09-17	Pfizer Products Incorporated	Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
UY30111A1 (es) *	2006-02-03	2007-04-30	Recordati Ireland Ltd	Sales de adicion de acido de n-(3-(4-(2-metoxifenil)-1-piperazinil)-propil)-7-oxo-5-trifluormetil-7h-tieno (3,2-b) piran-3-carboxamida
EP1991212A1 (en) *	2006-03-08	2008-11-19	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) *	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) *	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
EP2377531A2 (en)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
KR20090042227A (ko)	2006-06-06	2009-04-29	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US20080051413A1 (en) *	2006-08-25	2008-02-28	Kaohsiung Medical University	Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
EP2068872A1 (en) *	2006-09-08	2009-06-17	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008036678A2 (en) *	2006-09-19	2008-03-27	Braincells, Inc.	Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20080081816A1 (en) *	2006-10-03	2008-04-03	Kaohsiung Medical University	Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
US9006258B2 (en)	2006-12-05	2015-04-14	Intra-Cellular Therapies, Inc.	Method of treating female sexual dysfunction with a PDE1 inhibitor
CN101969774A (zh)	2007-12-06	2011-02-09	细胞内治疗公司	有机化合物
CA2740388A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
CN102231953A (zh)	2008-12-06	2011-11-02	细胞内治疗公司	有机化合物
PE20120120A1 (es)	2008-12-06	2012-03-03	Intra Cellular Therapies Inc	DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
WO2010065147A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
JP5710493B2 (ja)	2008-12-06	2015-04-30	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
US8633180B2 (en)	2008-12-06	2014-01-21	Intra-Cellular Therapies, Inc.	Organic compounds
JP2012513464A (ja)	2008-12-23	2012-06-14	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	ホスホジエステラーゼ阻害剤及びその使用
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en)	2009-02-27	2009-04-08	Vantia Ltd	New compounds
EP2434895A4 (en)	2009-05-13	2013-08-07	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
WO2011153135A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
WO2011153138A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
WO2012171016A1 (en)	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
WO2013067309A1 (en)	2011-11-04	2013-05-10	Xion Pharmaceutical Corporation	Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2804603A1 (en)	2012-01-10	2014-11-26	President and Fellows of Harvard College	Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en)	2012-01-17	2013-07-25	The Trustees Of Columbia University In The City Of New York	Novel phosphodiesterase inhibitors and uses thereof
AR091507A1 (es)	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
WO2014127331A1 (en)	2013-02-17	2014-08-21	Intra-Cellular Therapies, Inc.	Novel uses
US9545406B2 (en)	2013-03-15	2017-01-17	Intra-Cellular Therapies, Inc.	Method of treating a CNS injury with a PDE1 inhibitor
DK2970279T3 (da)	2013-03-15	2020-11-30	Intra Cellular Therapies Inc	Organiske forbindelser
RU2675851C2 (ru) *	2013-06-21	2018-12-25	Интра-Селлулар Терапиз, Инк.	Кристаллические формы свободного основания
ES2776353T3 (es)	2013-07-17	2020-07-30	Univ Columbia	Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
AR102315A1 (es) *	2014-04-02	2017-02-22	Bayer Cropscience Ag	Derivados de pirazolil-nicotin(tio)amida sustituidos y su uso como fungicidas
WO2015196186A1 (en)	2014-06-20	2015-12-23	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
JP6591530B2 (ja)	2014-08-07	2019-10-16	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
RU2711442C2 (ru)	2014-09-17	2020-01-17	Интра-Селлулар Терапиз, Инк.	Соединения и способы
EP3436083A4 (en)	2016-03-28	2019-11-27	Intra-Cellular Therapies, Inc.	NEW COMPOSITIONS AND METHODS
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
JP7076432B2 (ja)	2016-09-09	2022-05-27	インサイト・コーポレイション	Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AR109595A1 (es)	2016-09-09	2018-12-26	Incyte Corp	Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018049417A1 (en)	2016-09-12	2018-03-15	Intra-Cellular Therapies, Inc.	Novel uses
WO2018152220A1 (en)	2017-02-15	2018-08-23	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
WO2019152697A1 (en)	2018-01-31	2019-08-08	Intra-Cellular Therapies, Inc.	Novel uses
WO2019164847A1 (en)	2018-02-20	2019-08-29	Incyte Corporation	Indazole compounds and uses thereof
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
ES2922237T3 (es)	2018-02-20	2022-09-12	Incyte Corp	Derivados de N-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de HPK1 para tratar el cáncer
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
EP3856348B1 (en)	2018-09-25	2024-01-03	Incyte Corporation	Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
WO2021026180A1 (en)	2019-08-06	2021-02-11	Incyte Corporation	Solid forms of an hpk1 inhibitor
CN113493459B (zh) *	2020-04-07	2022-12-13	广州白云山医药集团股份有限公司白云山制药总厂	Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2089971A (en)		1937-08-17		Condensation products of
DE425921C (de) *	1923-08-11	1926-02-27	Ernst Otto Baum	Pressluftzugmaschine fuer Bergwerke
US4871843A (en)	1983-10-18	1989-10-03	Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle	Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
FR2558263B1 (fr) *	1984-01-12	1986-04-25	Commissariat Energie Atomique	Accelerometre directif et son procede de fabrication par microlithographie
US4663326A (en)	1985-04-04	1987-05-05	Warner-Lambert Company	Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
GB8817651D0 (en)	1988-07-25	1988-09-01	Smith Kline French Lab	Chemical compounds
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9202238D0 (en)	1992-02-03	1992-03-18	Wellcome Found	Compounds
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en)	1992-06-26	1998-03-31	Pfizer Inc	Purinone antianginal agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9311920D0 (en)	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
GB9315017D0 (en)	1993-07-20	1993-09-01	Glaxo Lab Sa	Chemical compounds
US5728705A (en)	1993-10-04	1998-03-17	The Trustees Of Columbia University In The City Of New York	Method of inducing vasorelaxation to treat pulmonary hypertension
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5656629A (en)	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
AU708809B2 (en)	1995-03-10	1999-08-12	Sanofi Pharmaceuticals, Inc.	6-aryl pyrazolo{3,4-d}pyrimidin-4-ones and compositions and methods of use thereof
US5952006A (en)	1995-09-29	1999-09-14	L.A.M. Pharmaceuticals, Llc	Drug preparations for treating impotency
DE19540642A1 (de)	1995-11-01	1997-05-07	Stief Christian Georg Priv Doz	Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
GB9612514D0 (en)	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
BR9810233A (pt) *	1997-04-25	2000-10-17	Pfizer	Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
ATE333279T1 (de)	1997-05-19	2006-08-15	Zonagen Inc	Kombinationstherapie zur modulation der humanen sexualreaktion
BR9809508A (pt)	1997-05-29	2000-06-20	Mochida Pharm Co Ltd	Agente terapêutico para disfunção de ereção
PL341575A1 (en)	1997-12-16	2001-04-23	Pfizer Prod Inc	Composition effective in treating impotency
PT1371647E (pt)	1998-04-20	2005-10-31	Pfizer	Derivados do acido piridina-3-carboxilico e sua utilizacao como intermediarios
WO1999059584A1 (en)	1998-05-20	1999-11-25	Schering Corporation	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6087368A (en)	1998-06-08	2000-07-11	Bristol-Myers Squibb Company	Quinazolinone inhibitors of cGMP phosphodiesterase
WO2000020033A1 (fr)	1998-10-05	2000-04-13	Eisai Co., Ltd.	Comprimes se delitant immediatement dans la cavite buccale
JP2000119198A (ja)	1998-10-16	2000-04-25	Eisai Co Ltd	苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
CA2251255A1 (en)	1998-10-20	2000-04-20	Mcgill University	The use of dopaminergic agents in the management of sexual dysfunction
IL132406A0 (en)	1998-10-21	2001-03-19	Pfizer Prod Inc	Treatment of bph with cgmp elevators
WO2000024745A1 (en)	1998-10-23	2000-05-04	Pfizer Limited	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
GB9823101D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
GB9828340D0 (en)	1998-12-22	1999-02-17	Novartis Ag	Organic compounds
JP3199115B2 (ja) *	1998-12-24	2001-08-13	モトローラ株式会社	デジタル・アナログ変換回路
DE19903087A1 (de)	1999-01-27	2000-08-10	Forssmann Wolf Georg	Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
EP1161255A4 (en)	1999-03-08	2002-07-17	Merck & Co Inc	METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
IL137429A0 (en)	1999-07-28	2001-07-24	Pfizer Prod Inc	Methods and compsitions for treating diseases and conditions of the eye
AU5957600A (en)	1999-07-30	2001-02-19	Lakefield Minerals Ltd.	Pharmaceutical compositions for topical application to treat erectile dysfunction
EP1246605A2 (en)	1999-08-10	2002-10-09	The Board Of Regents, The University Of Texas System	Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow
US6436944B1 (en)	1999-09-30	2002-08-20	Pfizer Inc.	Combination effective for the treatment of impotence
YU59100A (sh)	1999-10-11	2003-10-31	Pfizer Inc.	Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6420557B1 (en) *	2000-07-28	2002-07-16	Pfizer Inc.	Crystalline therapeutic agent
US6407259B1 (en) *	2000-07-28	2002-06-18	Pfizer Inc.	Process for the preparation of pyrazoles

2000
- 2000-09-14 TW TW089118861A patent/TWI265925B/zh not_active IP Right Cessation
- 2000-10-06 US US09/685,080 patent/US6677335B1/en not_active Expired - Fee Related
- 2000-10-09 EG EG20001281A patent/EG24411A/xx active
- 2000-10-09 PH PH12000002783A patent/PH12000002783B1/en unknown
- 2000-10-09 MY MYPI20004712A patent/MY130319A/en unknown
- 2000-10-10 PA PA20008504501A patent/PA8504501A1/es unknown
- 2000-10-10 GT GT200000171A patent/GT200000171A/es unknown
- 2000-10-10 TN TNTNSN00199A patent/TNSN00199A1/fr unknown
- 2000-10-11 CZ CZ20021158A patent/CZ20021158A3/cs unknown
- 2000-10-11 KR KR1020027004643A patent/KR100549152B1/ko not_active IP Right Cessation
- 2000-10-11 WO PCT/IB2000/001457 patent/WO2001027113A2/en active Application Filing
- 2000-10-11 AT AT00966347T patent/ATE284404T1/de not_active IP Right Cessation
- 2000-10-11 CA CA002387357A patent/CA2387357C/en not_active Expired - Fee Related
- 2000-10-11 ES ES00966347T patent/ES2232502T3/es not_active Expired - Lifetime
- 2000-10-11 GE GEAP20006408A patent/GEP20033142B/en unknown
- 2000-10-11 IL IL14902600A patent/IL149026A0/xx unknown
- 2000-10-11 CN CNB2005100625827A patent/CN100378100C/zh not_active Expired - Fee Related
- 2000-10-11 PT PT00966347T patent/PT1220856E/pt unknown
- 2000-10-11 DZ DZ003220A patent/DZ3220A1/fr active
- 2000-10-11 NZ NZ518078A patent/NZ518078A/en unknown
- 2000-10-11 PL PL00357536A patent/PL357536A1/xx not_active Application Discontinuation
- 2000-10-11 AU AU76784/00A patent/AU779065B2/en not_active Ceased
- 2000-10-11 BR BR0014698-6A patent/BR0014698A/pt not_active Application Discontinuation
- 2000-10-11 JP JP2001530331A patent/JP3834236B2/ja not_active Expired - Fee Related
- 2000-10-11 CN CNB008151954A patent/CN1204138C/zh not_active Expired - Fee Related
- 2000-10-11 DK DK00966347T patent/DK1220856T3/da active
- 2000-10-11 PE PE2000001090A patent/PE20010737A1/es not_active Application Discontinuation
- 2000-10-11 SK SK460-2002A patent/SK4602002A3/sk unknown
- 2000-10-11 OA OA1200200104A patent/OA12061A/en unknown
- 2000-10-11 SI SI200030593T patent/SI1220856T1/xx unknown
- 2000-10-11 SV SV2000000195A patent/SV2002000195A/es unknown
- 2000-10-11 DE DE60016615T patent/DE60016615T2/de not_active Expired - Lifetime
- 2000-10-11 CO CO00077467A patent/CO5251477A1/es not_active Application Discontinuation
- 2000-10-11 AP APAP/P/2002/002456A patent/AP1238A/en active
- 2000-10-11 RS YUP-314/02A patent/RS50476B/sr unknown
- 2000-10-11 EA EA200200337A patent/EA004982B1/ru not_active IP Right Cessation
- 2000-10-11 TR TR2002/00989T patent/TR200200989T2/xx unknown
- 2000-10-11 HU HU0203450A patent/HUP0203450A3/hu unknown
- 2000-10-11 GE GEAP20005578A patent/GEP20033068B/en unknown
- 2000-10-11 EE EEP200200195A patent/EE05181B1/xx not_active IP Right Cessation
- 2000-10-11 EP EP00966347A patent/EP1220856B1/en not_active Expired - Lifetime
- 2000-10-11 CN CNB2004100384099A patent/CN100383141C/zh not_active Expired - Fee Related
2002
- 2002-03-21 IS IS6320A patent/IS2181B/is unknown
- 2002-03-21 CU CU20020060A patent/CU23198A3/es not_active IP Right Cessation
- 2002-03-28 IN IN385MU2002 patent/IN2002MU00385A/en unknown
- 2002-04-05 MA MA26586A patent/MA26825A1/fr unknown
- 2002-04-08 CR CR6617A patent/CR6617A/es not_active Application Discontinuation
- 2002-04-08 IL IL149026A patent/IL149026A/en not_active IP Right Cessation
- 2002-04-10 MX MXPA02003627 patent/MX228340B/es active IP Right Grant
- 2002-04-10 NO NO20021694A patent/NO322856B1/no not_active IP Right Cessation
- 2002-04-11 HR HR20020317A patent/HRP20020317B1/xx not_active IP Right Cessation
- 2002-05-09 BG BG106678A patent/BG106678A/bg unknown
2003
- 2003-04-10 HK HK03102607A patent/HK1050367A1/xx not_active IP Right Cessation
2004
- 2004-01-06 US US10/753,199 patent/US7176311B2/en not_active Expired - Fee Related
2005
- 2005-01-28 IN IN80MU2005 patent/IN2005MU00080A/en unknown
- 2005-03-11 HK HK05102106A patent/HK1069577A1/xx not_active IP Right Cessation
- 2005-11-18 HK HK05110418A patent/HK1078574A1/xx not_active IP Right Cessation
2006
- 2006-03-08 IN IN264MU2006 patent/IN2006MU00264A/en unknown
- 2006-08-11 US US11/463,931 patent/US20060293347A1/en not_active Abandoned
2007
- 2007-04-19 IN IN567MU2007 patent/IN2007MU00567A/en unknown
2008
- 2008-08-08 CR CR10191A patent/CR10191A/es not_active Application Discontinuation
2009
- 2009-05-20 US US12/469,311 patent/US20100035891A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CO5251477A1 (es)	2003-02-28
SK4602002A3 (en)	2003-04-01
PL357536A1 (en)	2004-07-26
NO322856B1 (no)	2006-12-11
PH12000002783B1 (en)	2006-02-21
KR20020038942A (ko)	2002-05-24
CR6617A (es)	2004-02-23
WO2001027113A2 (en)	2001-04-19
GEP20033142B (en)	2003-12-25
DE60016615D1 (de)	2005-01-13
BR0014698A (pt)	2002-06-18
GEP20033068B (en)	2003-09-25
CN100378100C (zh)	2008-04-02
EP1220856B1 (en)	2004-12-08
WO2001027113A3 (en)	2001-10-25
NO20021694D0 (no)	2002-04-10
HRP20020317A2 (en)	2004-04-30
NZ518078A (en)	2003-10-31
IN2005MU00080A (da)	2006-05-19
CA2387357C (en)	2007-10-02
OA12061A (en)	2006-05-03
JP3834236B2 (ja)	2006-10-18
CU23198A3 (es)	2007-03-23
YU31402A (sh)	2005-03-15
TR200200989T2 (tr)	2002-09-23
US20060293347A1 (en)	2006-12-28
ES2232502T3 (es)	2005-06-01
US20100035891A1 (en)	2010-02-11
IS6320A (is)	2002-03-21
AU7678400A (en)	2001-04-23
CA2387357A1 (en)	2001-04-19
MXPA02003627A (en)	2002-08-01
KR100549152B1 (ko)	2006-02-06
JP2003511453A (ja)	2003-03-25
MA26825A1 (fr)	2004-12-20
AP2002002456A0 (en)	2002-06-30
AU779065B2 (en)	2005-01-06
MX228340B (en)	2005-06-07
EA004982B1 (ru)	2004-10-28
HK1050367A1 (en)	2003-06-20
IN2006MU00264A (da)	2007-06-08
US7176311B2 (en)	2007-02-13
EE200200195A (et)	2003-08-15
HUP0203450A2 (hu)	2003-01-28
PA8504501A1 (es)	2003-06-30
CN1572792A (zh)	2005-02-02
SV2002000195A (es)	2002-07-16
CN1680378A (zh)	2005-10-12
CN100383141C (zh)	2008-04-23
IL149026A0 (en)	2002-11-10
HUP0203450A3 (en)	2003-05-28
MY130319A (en)	2007-06-29
CN1204138C (zh)	2005-06-01
CR10191A (es)	2008-10-10
CZ20021158A3 (cs)	2003-03-12
US20040152712A1 (en)	2004-08-05
DE60016615T2 (de)	2005-12-22
ATE284404T1 (de)	2004-12-15
HK1078574A1 (en)	2006-03-17
BG106678A (bg)	2003-01-31
CN1387531A (zh)	2002-12-25
RS50476B (sr)	2010-03-02
EG24411A (en)	2009-05-25
HK1069577A1 (en)	2005-05-27
DZ3220A1 (fr)	2001-04-19
PT1220856E (pt)	2005-02-28
PE20010737A1 (es)	2001-07-19
NO20021694L (no)	2002-05-27
GT200000171A (es)	2002-04-03
EP1220856A2 (en)	2002-07-10
IN2007MU00567A (da)	2007-08-31
HRP20020317B1 (en)	2007-08-31
AP1238A (en)	2004-01-29
EA200200337A1 (ru)	2002-10-31
TNSN00199A1 (fr)	2002-05-30
US6677335B1 (en)	2004-01-13
IN2002MU00385A (da)	2005-08-26
EE05181B1 (et)	2009-06-15
SI1220856T1 (en)	2005-06-30
TWI265925B (en)	2006-11-11
IL149026A (en)	2010-05-17
IS2181B (is)	2006-12-15

Publication	Publication Date	Title
DE60016615D1 (de)	2005-01-13	Pyrazolo[4,3-d]pyrimidinderivate
MA26851A1 (fr)	2004-12-20	Derives de pyrrolo [2,3-d] pyrimidine
DK1087971T3 (da)	2004-10-11	Pyrrolo[2,3-d]pyrimidinforbindelser
DK1416935T3 (da)	2008-07-07	4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
DE69915675D1 (de)	2004-04-22	Triazolo[4,5-d]pyrimidin-derivate
ID26698A (id)	2001-02-01	SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
DE69804273D1 (de)	2002-04-25	5h-Thiazolo[3,2-a]pyrimidinderivate
DE50001191D1 (de)	2003-03-06	Pyrazolo[4, 3-d]pyrimidine
DE60103909D1 (de)	2004-07-22	2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
NO995033D0 (no)	1999-10-15	6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
PT1326866E (pt)	2005-08-31	3,4-di-hidropirido[1,2-a]pirimidinas substituidas
ZA200202763B (en)	2003-06-25	Pyrazolo [4,3-D] pyrimidine derivatives.
DK1326866T3 (da)	2005-08-01	Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner